Share Price and Basic Stock Data
Last Updated: December 31, 2025, 8:34 pm
| PEG Ratio | 2.68 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Torrent Pharmaceuticals Ltd, operating in the pharmaceuticals sector, reported a current stock price of ₹3,822 and a market capitalization of ₹1,29,393 Cr. The company has shown consistent revenue growth, with sales increasing from ₹8,508 Cr in FY 2022 to ₹9,620 Cr in FY 2023, and projected to reach ₹10,728 Cr in FY 2024. The trailing twelve months (TTM) sales figure stood at ₹12,248 Cr, indicating robust performance. Quarterly sales have also demonstrated an upward trend, with ₹2,660 Cr in Q2 FY 2024, marking a rise from ₹2,591 Cr in Q1 FY 2024. This growth trajectory reflects the company’s ability to adapt to market demands and expand its product offerings effectively. The operating profit margin (OPM) remained stable at around 33%, showcasing efficient cost management while navigating a competitive landscape.
Profitability and Efficiency Metrics
Torrent Pharmaceuticals reported a net profit of ₹2,140 Cr, translating to a remarkable return on equity (ROE) of 26.5% and a return on capital employed (ROCE) of 27.0%. These figures indicate that the company is effectively utilizing its capital to generate profits. The operating profit for the latest fiscal year reached ₹3,721 Cr, with an OPM of 32% for FY 2025, reflecting operational efficiency. The interest coverage ratio stood at an impressive 14.84x, suggesting strong earnings relative to its interest obligations, which is significantly above the typical sector range. However, the cash conversion cycle (CCC) of 154 days indicates a potential area for improvement in working capital management, as it is higher than the industry average, potentially affecting liquidity.
Balance Sheet Strength and Financial Ratios
The balance sheet of Torrent Pharmaceuticals is characterized by a sound capital structure, with total borrowings reported at ₹2,822 Cr against reserves of ₹8,280 Cr. The debt-to-equity ratio stood at 0.39, reflecting a low level of leverage, which is favorable compared to industry norms. The company’s current ratio of 1.19 suggests adequate short-term liquidity to cover its obligations. Furthermore, the price-to-book value (P/BV) ratio of 14.42x indicates a premium valuation compared to its book value of ₹224.27 per share. This premium could be justified by the company’s strong profitability metrics and growth potential. However, the increase in borrowings from ₹4,070 Cr in FY 2022 to ₹5,369 Cr in FY 2023 raises questions about long-term financial sustainability if not managed prudently.
Shareholding Pattern and Investor Confidence
The shareholding structure of Torrent Pharmaceuticals showcases a strong promoter holding of 68.31%, indicating significant insider confidence in the company’s future. Foreign Institutional Investors (FIIs) hold 15.92%, while Domestic Institutional Investors (DIIs) account for 9.17%, reflecting a diversified investor base. The number of shareholders has increased to 78,226, suggesting growing public interest in the stock. However, the promoter stake has seen a decline from 71.25% in December 2022 to the current level, which may raise concerns about dilution of control. The steady increase in FII participation indicates positive sentiment among foreign investors, which often correlates with improved market perception. This level of institutional support is crucial for maintaining stock stability and investor confidence.
Outlook, Risks, and Final Insight
The outlook for Torrent Pharmaceuticals remains positive, driven by its solid revenue growth and strong profitability metrics. However, potential risks include the rising borrowings that may impact financial flexibility and the high cash conversion cycle, which could strain liquidity in challenging market conditions. Additionally, competition within the pharmaceutical sector, particularly from generics and biosimilars, poses a threat to market share. The company’s ability to innovate and expand its product line will be critical in mitigating these risks. Should it maintain its operational efficiency and manage its debt prudently, Torrent Pharmaceuticals could capitalize on growth opportunities in both domestic and international markets, solidifying its position as a leading player in the pharmaceutical industry.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 129 Cr. | 103 | 231/84.3 | 28.6 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,816 Cr. | 442 | 479/192 | 99.7 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.3 Cr. | 43.5 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 52.4 Cr. | 35.8 | 36.4/17.0 | 125 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,197.40 Cr | 1,153.64 | 53.52 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,291 | 2,491 | 2,491 | 2,591 | 2,660 | 2,732 | 2,745 | 2,859 | 2,889 | 2,809 | 2,959 | 3,178 | 3,302 |
| Expenses | 1,612 | 1,767 | 1,764 | 1,800 | 1,835 | 1,863 | 1,862 | 1,955 | 1,950 | 1,895 | 1,995 | 2,146 | 2,219 |
| Operating Profit | 679 | 724 | 727 | 791 | 825 | 869 | 883 | 904 | 939 | 914 | 964 | 1,032 | 1,083 |
| OPM % | 30% | 29% | 29% | 31% | 31% | 32% | 32% | 32% | 32% | 33% | 33% | 32% | 33% |
| Other Income | 16 | -10 | 9 | 34 | 26 | 55 | 31 | 24 | -16 | 33 | -42 | -37 | -40 |
| Interest | 69 | 102 | 107 | 103 | 91 | 80 | 80 | 75 | 64 | 57 | 56 | 56 | 48 |
| Depreciation | 163 | 193 | 196 | 191 | 201 | 213 | 203 | 197 | 198 | 199 | 201 | 201 | 204 |
| Profit before tax | 463 | 419 | 433 | 531 | 559 | 631 | 631 | 656 | 661 | 691 | 665 | 738 | 791 |
| Tax % | 33% | 30% | 34% | 29% | 31% | 30% | 29% | 30% | 31% | 27% | 25% | 26% | 25% |
| Net Profit | 312 | 292 | 287 | 378 | 386 | 443 | 449 | 457 | 453 | 503 | 498 | 548 | 591 |
| EPS in Rs | 9.22 | 8.63 | 8.48 | 11.17 | 11.41 | 13.09 | 13.27 | 13.50 | 13.38 | 14.86 | 14.71 | 16.19 | 17.46 |
Last Updated: December 28, 2025, 7:03 pm
Below is a detailed analysis of the quarterly data for Torrent Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 3,302.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,178.00 Cr. (Jun 2025) to 3,302.00 Cr., marking an increase of 124.00 Cr..
- For Expenses, as of Sep 2025, the value is 2,219.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,146.00 Cr. (Jun 2025) to 2,219.00 Cr., marking an increase of 73.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 1,083.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,032.00 Cr. (Jun 2025) to 1,083.00 Cr., marking an increase of 51.00 Cr..
- For OPM %, as of Sep 2025, the value is 33.00%. The value appears strong and on an upward trend. It has increased from 32.00% (Jun 2025) to 33.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is -40.00 Cr.. The value appears to be declining and may need further review. It has decreased from -37.00 Cr. (Jun 2025) to -40.00 Cr., marking a decrease of 3.00 Cr..
- For Interest, as of Sep 2025, the value is 48.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 56.00 Cr. (Jun 2025) to 48.00 Cr., marking a decrease of 8.00 Cr..
- For Depreciation, as of Sep 2025, the value is 204.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 201.00 Cr. (Jun 2025) to 204.00 Cr., marking an increase of 3.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 791.00 Cr.. The value appears strong and on an upward trend. It has increased from 738.00 Cr. (Jun 2025) to 791.00 Cr., marking an increase of 53.00 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Jun 2025) to 25.00%, marking a decrease of 1.00%.
- For Net Profit, as of Sep 2025, the value is 591.00 Cr.. The value appears strong and on an upward trend. It has increased from 548.00 Cr. (Jun 2025) to 591.00 Cr., marking an increase of 43.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 17.46. The value appears strong and on an upward trend. It has increased from 16.19 (Jun 2025) to 17.46, marking an increase of 1.27.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:29 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,172 | 4,636 | 6,687 | 5,816 | 5,950 | 7,673 | 7,939 | 8,005 | 8,508 | 9,620 | 10,728 | 11,516 | 12,248 |
| Expenses | 3,216 | 3,616 | 3,954 | 4,438 | 4,601 | 5,690 | 5,769 | 5,524 | 6,077 | 6,778 | 7,360 | 7,795 | 8,255 |
| Operating Profit | 955 | 1,020 | 2,733 | 1,377 | 1,349 | 1,983 | 2,170 | 2,480 | 2,431 | 2,842 | 3,368 | 3,721 | 3,993 |
| OPM % | 23% | 22% | 41% | 24% | 23% | 26% | 27% | 31% | 29% | 30% | 31% | 32% | 33% |
| Other Income | 34 | 286 | 32 | 223 | 299 | -300 | 121 | 57 | -288 | 45 | 146 | -1 | -86 |
| Interest | 59 | 175 | 184 | 206 | 308 | 504 | 451 | 353 | 255 | 333 | 354 | 252 | 217 |
| Depreciation | 87 | 191 | 238 | 307 | 409 | 618 | 654 | 658 | 662 | 707 | 808 | 795 | 805 |
| Profit before tax | 844 | 940 | 2,343 | 1,088 | 931 | 562 | 1,187 | 1,526 | 1,226 | 1,847 | 2,352 | 2,673 | 2,885 |
| Tax % | 21% | 20% | 26% | 14% | 27% | 22% | 14% | 18% | 37% | 33% | 30% | 28% | |
| Net Profit | 664 | 751 | 1,733 | 934 | 678 | 436 | 1,025 | 1,252 | 777 | 1,245 | 1,656 | 1,911 | 2,140 |
| EPS in Rs | 19.62 | 22.19 | 51.22 | 27.59 | 20.04 | 12.89 | 30.28 | 36.99 | 22.97 | 36.79 | 48.94 | 56.47 | 63.22 |
| Dividend Payout % | 25% | 25% | 34% | 25% | 35% | 66% | 53% | 47% | 105% | 60% | 57% | 57% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 13.10% | 130.76% | -46.11% | -27.41% | -35.69% | 135.09% | 22.15% | -37.94% | 60.23% | 33.01% | 15.40% |
| Change in YoY Net Profit Growth (%) | 0.00% | 117.66% | -176.86% | 18.70% | -8.28% | 170.78% | -112.95% | -60.09% | 98.17% | -27.22% | -17.61% |
Torrent Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 8% |
| 3 Years: | 11% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 14% |
| 3 Years: | 21% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 21% |
| 3 Years: | 34% |
| 1 Year: | 5% |
| Return on Equity | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 23% |
| 3 Years: | 24% |
| Last Year: | 27% |
Last Updated: September 5, 2025, 1:46 pm
Balance Sheet
Last Updated: December 4, 2025, 2:07 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 169 | 169 | 169 | 169 |
| Reserves | 1,818 | 2,406 | 3,409 | 4,266 | 4,538 | 4,640 | 4,739 | 5,753 | 5,868 | 6,029 | 6,687 | 7,421 | 8,280 |
| Borrowings | 1,132 | 2,740 | 2,352 | 2,510 | 6,462 | 6,038 | 5,784 | 4,874 | 4,070 | 5,369 | 4,022 | 3,202 | 2,822 |
| Other Liabilities | 1,988 | 2,589 | 3,040 | 2,740 | 3,159 | 3,351 | 3,402 | 3,363 | 2,884 | 3,043 | 3,627 | 3,603 | 4,244 |
| Total Liabilities | 5,022 | 7,820 | 8,886 | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 14,610 | 14,505 | 14,396 | 15,515 |
| Fixed Assets | 875 | 2,833 | 2,859 | 3,688 | 7,855 | 7,748 | 7,533 | 7,065 | 6,423 | 8,121 | 8,138 | 7,947 | 7,841 |
| CWIP | 534 | 678 | 1,042 | 519 | 647 | 617 | 712 | 889 | 630 | 765 | 361 | 478 | 488 |
| Investments | 186 | 298 | 780 | 804 | 492 | 353 | 2 | 181 | 226 | 199 | 173 | 156 | 133 |
| Other Assets | 3,427 | 4,011 | 4,206 | 4,589 | 5,249 | 5,395 | 5,763 | 5,940 | 5,628 | 5,524 | 5,834 | 5,815 | 7,053 |
| Total Assets | 5,022 | 7,820 | 8,886 | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 14,610 | 14,505 | 14,396 | 15,515 |
Below is a detailed analysis of the balance sheet data for Torrent Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 169.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 169.00 Cr..
- For Reserves, as of Sep 2025, the value is 8,280.00 Cr.. The value appears strong and on an upward trend. It has increased from 7,421.00 Cr. (Mar 2025) to 8,280.00 Cr., marking an increase of 859.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2,822.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 3,202.00 Cr. (Mar 2025) to 2,822.00 Cr., marking a decrease of 380.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 4,244.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,603.00 Cr. (Mar 2025) to 4,244.00 Cr., marking an increase of 641.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 15,515.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14,396.00 Cr. (Mar 2025) to 15,515.00 Cr., marking an increase of 1,119.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 7,841.00 Cr.. The value appears to be declining and may need further review. It has decreased from 7,947.00 Cr. (Mar 2025) to 7,841.00 Cr., marking a decrease of 106.00 Cr..
- For CWIP, as of Sep 2025, the value is 488.00 Cr.. The value appears strong and on an upward trend. It has increased from 478.00 Cr. (Mar 2025) to 488.00 Cr., marking an increase of 10.00 Cr..
- For Investments, as of Sep 2025, the value is 133.00 Cr.. The value appears to be declining and may need further review. It has decreased from 156.00 Cr. (Mar 2025) to 133.00 Cr., marking a decrease of 23.00 Cr..
- For Other Assets, as of Sep 2025, the value is 7,053.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,815.00 Cr. (Mar 2025) to 7,053.00 Cr., marking an increase of 1,238.00 Cr..
- For Total Assets, as of Sep 2025, the value is 15,515.00 Cr.. The value appears strong and on an upward trend. It has increased from 14,396.00 Cr. (Mar 2025) to 15,515.00 Cr., marking an increase of 1,119.00 Cr..
Notably, the Reserves (8,280.00 Cr.) exceed the Borrowings (2,822.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 954.00 | -1.00 | 0.00 | -1.00 | -5.00 | -5.00 | -3.00 | -2.00 | -2.00 | -3.00 | -1.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 96 | 125 | 79 | 60 | 77 | 68 | 76 | 69 | 70 | 74 | 63 | 59 |
| Inventory Days | 297 | 275 | 314 | 318 | 429 | 318 | 362 | 456 | 368 | 298 | 310 | 334 |
| Days Payable | 421 | 472 | 523 | 356 | 447 | 345 | 345 | 351 | 250 | 224 | 284 | 239 |
| Cash Conversion Cycle | -28 | -71 | -130 | 21 | 59 | 42 | 93 | 174 | 188 | 147 | 89 | 154 |
| Working Capital Days | 24 | 29 | -1 | 28 | -80 | -62 | -52 | -5 | 7 | -33 | -27 | 7 |
| ROCE % | 35% | 27% | 48% | 19% | 13% | 13% | 15% | 17% | 19% | 20% | 23% | 27% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Large Cap Fund | 3,180,904 | 2.91 | 1183.49 | N/A | N/A | N/A |
| Axis Large Cap Fund | 946,972 | 1.03 | 352.33 | N/A | N/A | N/A |
| Franklin India Large Cap Fund | 846,654 | 3.91 | 315.01 | N/A | N/A | N/A |
| UTI Flexi Cap Fund | 735,300 | 1.07 | 273.58 | 742,000 | 2025-12-15 07:43:42 | -0.9% |
| Canara Robeco Large Cap Fund | 407,164 | 0.86 | 151.49 | N/A | N/A | N/A |
| SBI Healthcare Opportunities Fund | 400,000 | 3.6 | 148.82 | N/A | N/A | N/A |
| Axis Large & Mid Cap Fund | 387,176 | 0.92 | 144.05 | N/A | N/A | N/A |
| HDFC Large and Mid Cap Fund | 336,766 | 0.43 | 125.3 | N/A | N/A | N/A |
| Axis ELSS Tax Saver Fund | 330,930 | 0.35 | 123.13 | N/A | N/A | N/A |
| Nippon India Value Fund | 328,626 | 1.32 | 122.27 | 353,626 | 2025-11-03 03:03:49 | -7.07% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 56.47 | 48.94 | 36.79 | 45.93 | 73.98 |
| Diluted EPS (Rs.) | 56.47 | 48.94 | 36.79 | 45.93 | 73.98 |
| Cash EPS (Rs.) | 79.96 | 72.82 | 57.67 | 85.05 | 112.84 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 224.27 | 202.57 | 183.13 | 351.75 | 344.90 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 224.27 | 202.57 | 183.13 | 351.75 | 344.90 |
| Revenue From Operations / Share (Rs.) | 340.25 | 316.96 | 284.23 | 502.72 | 472.97 |
| PBDIT / Share (Rs.) | 110.63 | 101.21 | 85.30 | 155.27 | 149.90 |
| PBIT / Share (Rs.) | 87.14 | 77.33 | 64.43 | 116.15 | 111.04 |
| PBT / Share (Rs.) | 78.97 | 69.49 | 54.58 | 72.44 | 90.18 |
| Net Profit / Share (Rs.) | 56.47 | 48.94 | 36.79 | 45.92 | 73.97 |
| NP After MI And SOA / Share (Rs.) | 56.47 | 48.94 | 36.79 | 45.92 | 73.97 |
| PBDIT Margin (%) | 32.51 | 31.93 | 30.01 | 30.88 | 31.69 |
| PBIT Margin (%) | 25.61 | 24.39 | 22.66 | 23.10 | 23.47 |
| PBT Margin (%) | 23.20 | 21.92 | 19.20 | 14.40 | 19.06 |
| Net Profit Margin (%) | 16.59 | 15.44 | 12.94 | 9.13 | 15.63 |
| NP After MI And SOA Margin (%) | 16.59 | 15.44 | 12.94 | 9.13 | 15.63 |
| Return on Networth / Equity (%) | 25.17 | 24.15 | 20.09 | 13.05 | 21.44 |
| Return on Capital Employeed (%) | 28.71 | 27.16 | 22.79 | 22.63 | 20.46 |
| Return On Assets (%) | 12.75 | 10.99 | 8.29 | 5.93 | 8.89 |
| Long Term Debt / Equity (X) | 0.15 | 0.23 | 0.40 | 0.35 | 0.50 |
| Total Debt / Equity (X) | 0.39 | 0.57 | 0.85 | 0.67 | 0.82 |
| Asset Turnover Ratio (%) | 0.76 | 0.71 | 0.68 | 0.53 | 0.50 |
| Current Ratio (X) | 1.19 | 1.03 | 0.97 | 1.20 | 1.13 |
| Quick Ratio (X) | 0.65 | 0.61 | 0.56 | 0.64 | 0.58 |
| Inventory Turnover Ratio (X) | 4.78 | 0.73 | 0.63 | 0.68 | 0.69 |
| Dividend Payout Ratio (NP) (%) | 56.66 | 61.29 | 69.30 | 87.09 | 27.03 |
| Dividend Payout Ratio (CP) (%) | 40.02 | 41.19 | 44.21 | 47.02 | 17.72 |
| Earning Retention Ratio (%) | 43.34 | 38.71 | 30.70 | 12.91 | 72.97 |
| Cash Earning Retention Ratio (%) | 59.98 | 58.81 | 55.79 | 52.98 | 82.28 |
| Interest Coverage Ratio (X) | 14.84 | 9.69 | 8.66 | 10.30 | 7.19 |
| Interest Coverage Ratio (Post Tax) (X) | 8.67 | 5.43 | 4.73 | 5.95 | 4.55 |
| Enterprise Value (Cr.) | 111924.90 | 91136.90 | 56758.99 | 50939.27 | 47229.23 |
| EV / Net Operating Revenue (X) | 9.72 | 8.50 | 5.90 | 5.99 | 5.90 |
| EV / EBITDA (X) | 29.89 | 26.60 | 19.66 | 19.38 | 18.62 |
| MarketCap / Net Operating Revenue (X) | 9.51 | 8.21 | 5.41 | 5.56 | 5.37 |
| Retention Ratios (%) | 43.33 | 38.70 | 30.69 | 12.90 | 72.96 |
| Price / BV (X) | 14.42 | 12.84 | 8.39 | 7.95 | 7.37 |
| Price / Net Operating Revenue (X) | 9.51 | 8.21 | 5.41 | 5.56 | 5.37 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.01 | 0.02 |
After reviewing the key financial ratios for Torrent Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 56.47. This value is within the healthy range. It has increased from 48.94 (Mar 24) to 56.47, marking an increase of 7.53.
- For Diluted EPS (Rs.), as of Mar 25, the value is 56.47. This value is within the healthy range. It has increased from 48.94 (Mar 24) to 56.47, marking an increase of 7.53.
- For Cash EPS (Rs.), as of Mar 25, the value is 79.96. This value is within the healthy range. It has increased from 72.82 (Mar 24) to 79.96, marking an increase of 7.14.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 224.27. It has increased from 202.57 (Mar 24) to 224.27, marking an increase of 21.70.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 224.27. It has increased from 202.57 (Mar 24) to 224.27, marking an increase of 21.70.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 340.25. It has increased from 316.96 (Mar 24) to 340.25, marking an increase of 23.29.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 110.63. This value is within the healthy range. It has increased from 101.21 (Mar 24) to 110.63, marking an increase of 9.42.
- For PBIT / Share (Rs.), as of Mar 25, the value is 87.14. This value is within the healthy range. It has increased from 77.33 (Mar 24) to 87.14, marking an increase of 9.81.
- For PBT / Share (Rs.), as of Mar 25, the value is 78.97. This value is within the healthy range. It has increased from 69.49 (Mar 24) to 78.97, marking an increase of 9.48.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 56.47. This value is within the healthy range. It has increased from 48.94 (Mar 24) to 56.47, marking an increase of 7.53.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 56.47. This value is within the healthy range. It has increased from 48.94 (Mar 24) to 56.47, marking an increase of 7.53.
- For PBDIT Margin (%), as of Mar 25, the value is 32.51. This value is within the healthy range. It has increased from 31.93 (Mar 24) to 32.51, marking an increase of 0.58.
- For PBIT Margin (%), as of Mar 25, the value is 25.61. This value exceeds the healthy maximum of 20. It has increased from 24.39 (Mar 24) to 25.61, marking an increase of 1.22.
- For PBT Margin (%), as of Mar 25, the value is 23.20. This value is within the healthy range. It has increased from 21.92 (Mar 24) to 23.20, marking an increase of 1.28.
- For Net Profit Margin (%), as of Mar 25, the value is 16.59. This value exceeds the healthy maximum of 10. It has increased from 15.44 (Mar 24) to 16.59, marking an increase of 1.15.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.59. This value is within the healthy range. It has increased from 15.44 (Mar 24) to 16.59, marking an increase of 1.15.
- For Return on Networth / Equity (%), as of Mar 25, the value is 25.17. This value is within the healthy range. It has increased from 24.15 (Mar 24) to 25.17, marking an increase of 1.02.
- For Return on Capital Employeed (%), as of Mar 25, the value is 28.71. This value is within the healthy range. It has increased from 27.16 (Mar 24) to 28.71, marking an increase of 1.55.
- For Return On Assets (%), as of Mar 25, the value is 12.75. This value is within the healthy range. It has increased from 10.99 (Mar 24) to 12.75, marking an increase of 1.76.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.15. This value is below the healthy minimum of 0.2. It has decreased from 0.23 (Mar 24) to 0.15, marking a decrease of 0.08.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.39. This value is within the healthy range. It has decreased from 0.57 (Mar 24) to 0.39, marking a decrease of 0.18.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.76. It has increased from 0.71 (Mar 24) to 0.76, marking an increase of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.19. This value is below the healthy minimum of 1.5. It has increased from 1.03 (Mar 24) to 1.19, marking an increase of 0.16.
- For Quick Ratio (X), as of Mar 25, the value is 0.65. This value is below the healthy minimum of 1. It has increased from 0.61 (Mar 24) to 0.65, marking an increase of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.78. This value is within the healthy range. It has increased from 0.73 (Mar 24) to 4.78, marking an increase of 4.05.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 56.66. This value exceeds the healthy maximum of 50. It has decreased from 61.29 (Mar 24) to 56.66, marking a decrease of 4.63.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 40.02. This value is within the healthy range. It has decreased from 41.19 (Mar 24) to 40.02, marking a decrease of 1.17.
- For Earning Retention Ratio (%), as of Mar 25, the value is 43.34. This value is within the healthy range. It has increased from 38.71 (Mar 24) to 43.34, marking an increase of 4.63.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 59.98. This value is within the healthy range. It has increased from 58.81 (Mar 24) to 59.98, marking an increase of 1.17.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 14.84. This value is within the healthy range. It has increased from 9.69 (Mar 24) to 14.84, marking an increase of 5.15.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.67. This value is within the healthy range. It has increased from 5.43 (Mar 24) to 8.67, marking an increase of 3.24.
- For Enterprise Value (Cr.), as of Mar 25, the value is 111,924.90. It has increased from 91,136.90 (Mar 24) to 111,924.90, marking an increase of 20,788.00.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.72. This value exceeds the healthy maximum of 3. It has increased from 8.50 (Mar 24) to 9.72, marking an increase of 1.22.
- For EV / EBITDA (X), as of Mar 25, the value is 29.89. This value exceeds the healthy maximum of 15. It has increased from 26.60 (Mar 24) to 29.89, marking an increase of 3.29.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 9.51. This value exceeds the healthy maximum of 3. It has increased from 8.21 (Mar 24) to 9.51, marking an increase of 1.30.
- For Retention Ratios (%), as of Mar 25, the value is 43.33. This value is within the healthy range. It has increased from 38.70 (Mar 24) to 43.33, marking an increase of 4.63.
- For Price / BV (X), as of Mar 25, the value is 14.42. This value exceeds the healthy maximum of 3. It has increased from 12.84 (Mar 24) to 14.42, marking an increase of 1.58.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 9.51. This value exceeds the healthy maximum of 3. It has increased from 8.21 (Mar 24) to 9.51, marking an increase of 1.30.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Torrent Pharmaceuticals Ltd:
- Net Profit Margin: 16.59%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 28.71% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 25.17% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8.67
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.65
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 60.2 (Industry average Stock P/E: 53.52)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.39
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 16.59%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Torrent House, Off Ashram Road, Ahmedabad Gujarat 380009 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sudhir Mehta | Chairman Emeritus |
| Mr. Samir Mehta | Executive Chairman |
| Mr. Aman Samir Mehta | Whole Time Director |
| Mr. Jinal Mehta | Non Executive Director |
| Mr. Manish Mahendra Choksi | Independent Director |
| Mr. Nikhil Khattau | Independent Director |
| Ms. Ameera Shah | Independent Director |
| Ms. Nayantara Bali | Independent Director |
FAQ
What is the intrinsic value of Torrent Pharmaceuticals Ltd?
Torrent Pharmaceuticals Ltd's intrinsic value (as of 31 December 2025) is ₹3217.08 which is 16.44% lower the current market price of ₹3,850.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,30,358 Cr. market cap, FY2025-2026 high/low of ₹3,882/2,886, reserves of ₹8,280 Cr, and liabilities of ₹15,515 Cr.
What is the Market Cap of Torrent Pharmaceuticals Ltd?
The Market Cap of Torrent Pharmaceuticals Ltd is 1,30,358 Cr..
What is the current Stock Price of Torrent Pharmaceuticals Ltd as on 31 December 2025?
The current stock price of Torrent Pharmaceuticals Ltd as on 31 December 2025 is ₹3,850.
What is the High / Low of Torrent Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Torrent Pharmaceuticals Ltd stocks is ₹3,882/2,886.
What is the Stock P/E of Torrent Pharmaceuticals Ltd?
The Stock P/E of Torrent Pharmaceuticals Ltd is 60.2.
What is the Book Value of Torrent Pharmaceuticals Ltd?
The Book Value of Torrent Pharmaceuticals Ltd is 250.
What is the Dividend Yield of Torrent Pharmaceuticals Ltd?
The Dividend Yield of Torrent Pharmaceuticals Ltd is 0.83 %.
What is the ROCE of Torrent Pharmaceuticals Ltd?
The ROCE of Torrent Pharmaceuticals Ltd is 27.0 %.
What is the ROE of Torrent Pharmaceuticals Ltd?
The ROE of Torrent Pharmaceuticals Ltd is 26.5 %.
What is the Face Value of Torrent Pharmaceuticals Ltd?
The Face Value of Torrent Pharmaceuticals Ltd is 5.00.